Regenxbio Inc (FRA:RB0)
€ 11.7 0.2 (1.72%) Market Cap: 612.88 Mil Enterprise Value: 382.14 Mil PE Ratio: 0 PB Ratio: 1.62 GF Score: 65/100

Regenxbio Inc To Discuss Interim Clinical Data Transcript

Mar 05, 2024 / 01:30PM GMT
Release Date Price: €19.5 (+0.52%)
Operator

(Operator Instructions)

With that, I will now turn the call over to Ken Mills, CEO of REGENXBIO.

Ken Mills
REGENXBIO Inc. - President & CEO

Good morning, everyone and thanks for joining us today. Today, we're excited to share new positive efficacy data from the AFFINITY DUCHENNE trial of RGX-202 for the treatment of Duchenne. Since our last update on February 7, we continue to be very encouraged by the data we have observed in this trial. (Event Instructions) Turning to the second slide of this presentation, you will see that today's event will include forward-looking statements and here is our forward-looking statement's disclosure. Please be advised that today's call is being recorded and webcast.

Okay. Let's move to slide 3 and here's our agenda. I will give an overview of today's positive updates. Then Dr. Steve Pakola, our Chief Medical Officer, will review the data from the AFFINITY DUCHENNE trial. Importantly, we're pleased to have Dr. Aravindhan Veerapandiyan, principle trial investigator on today's call and to engage in a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot